DK3127545T3 - Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer - Google Patents

Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer Download PDF

Info

Publication number
DK3127545T3
DK3127545T3 DK15774351.9T DK15774351T DK3127545T3 DK 3127545 T3 DK3127545 T3 DK 3127545T3 DK 15774351 T DK15774351 T DK 15774351T DK 3127545 T3 DK3127545 T3 DK 3127545T3
Authority
DK
Denmark
Prior art keywords
compound
medicine containing
antitumor medicine
efficiency promoter
tumor efficiency
Prior art date
Application number
DK15774351.9T
Other languages
English (en)
Inventor
Hiroyuki Okabe
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3127545T3 publication Critical patent/DK3127545T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15774351.9T 2014-04-04 2015-04-03 Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer DK3127545T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014078243 2014-04-04
PCT/JP2015/060645 WO2015152409A1 (ja) 2014-04-04 2015-04-03 タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤

Publications (1)

Publication Number Publication Date
DK3127545T3 true DK3127545T3 (da) 2020-08-10

Family

ID=54240716

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15774351.9T DK3127545T3 (da) 2014-04-04 2015-04-03 Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer

Country Status (14)

Country Link
US (2) US20170112866A1 (da)
EP (1) EP3127545B1 (da)
JP (1) JP6488280B2 (da)
AU (1) AU2015242788B2 (da)
DK (1) DK3127545T3 (da)
ES (1) ES2806449T3 (da)
HU (1) HUE051014T2 (da)
NZ (1) NZ725303A (da)
PL (1) PL3127545T3 (da)
PT (1) PT3127545T (da)
RU (1) RU2693463C2 (da)
UA (1) UA120611C2 (da)
WO (1) WO2015152409A1 (da)
ZA (1) ZA201607067B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102216772B1 (ko) * 2018-05-18 2021-02-17 주식회사 종근당 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1485127T3 (da) * 2002-02-25 2011-10-03 Elan Pharm Inc Anvendelse af midler til behandling af inflammation
CN101080227B (zh) * 2004-12-15 2011-08-31 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
WO2011069962A1 (en) * 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
TWI619509B (zh) * 2010-02-23 2018-04-01 建南德克公司 治療先前未經治療之ⅲ期或ⅳ期卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、太平洋紫杉醇與抗-vegf抗體之組合
BR112014002361A2 (pt) * 2011-08-02 2019-05-14 Astellas Pharma Inc. método para tratamento de câncer pelo uso combinado de fármacos
PL2908865T3 (pl) * 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka

Also Published As

Publication number Publication date
UA120611C2 (uk) 2020-01-10
EP3127545A1 (en) 2017-02-08
US20170112866A1 (en) 2017-04-27
RU2016143243A (ru) 2018-05-07
JP6488280B2 (ja) 2019-03-20
HUE051014T2 (hu) 2021-01-28
JPWO2015152409A1 (ja) 2017-04-13
US20250205269A1 (en) 2025-06-26
WO2015152409A1 (ja) 2015-10-08
ES2806449T3 (es) 2021-02-17
EP3127545A4 (en) 2017-11-22
AU2015242788B2 (en) 2018-10-25
PT3127545T (pt) 2020-07-20
RU2693463C2 (ru) 2019-07-03
EP3127545B1 (en) 2020-06-03
PL3127545T3 (pl) 2020-11-16
RU2016143243A3 (da) 2018-07-17
ZA201607067B (en) 2017-09-27
AU2015242788A1 (en) 2016-11-17
NZ725303A (en) 2019-02-22

Similar Documents

Publication Publication Date Title
LT3240801T (lt) Kombinuota navikų imunoterapija
LT3236972T (lt) Antivirusiniai n4-hidroksicitidino dariniai
EP3347340A4 (en) LYMPHENLEITUNGSPRODRUGS
DK3188717T3 (da) Formulering, der omfatter partikler
EP3094342A4 (en) Anti-tumor therapy
GB201600789D0 (en) Concentric pumped riser solution
HUE046707T2 (hu) Szállítószerkezet
IL246364A0 (en) Simultaneous dual-band detector
GB201502252D0 (en) Carrier
EP3310915A4 (en) TUMOR IMMUNOTHERAPY
DK3158846T3 (da) Bæreanordning
DK3253749T3 (da) Forbindelser med antitumoraktivitet
AP2016009629A0 (en) Shale gas extraction
PT3144626T (pt) Estrutura de transporte pirotécnico
GB201410723D0 (en) Proppants
HUE057728T2 (hu) Szubsztrátumhordozó
DE112016000932A5 (de) Radträger
EP3146119C0 (de) Pneumatischer träger
EP3395363A4 (en) ANTIVIRAL MEDICINAL PRODUCT
DK3178837T3 (da) Urlc10-afledt peptid og vaccine, der indeholder dette
DK3127545T3 (da) Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer
PL3127544T3 (pl) Lek przeciwnowotworowy zawierający przeciwnowotworowy kompleks platyny i wzmacniacz działania przeciwnowotworowego
GB201415857D0 (en) Laminated structure
LT3484852T (lt) Benzo-n-hidroksiamido junginiai, turintys priešnavikinį aktyvumą
EP3111944A4 (en) Antiviral drug